ArticleLeukemia2020
BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 55 citations in OpenAlex.
- Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions.Journal of advanced research · 2026Review
- A comprehensive review of using nanomaterials in cancer immunotherapy: Pros and Cons of clinical usage.3 Biotech · 2025Review
- Nanotechnology in Hematology: Enhancing Therapeutic Efficacy With Nanoparticles.Health science reports · 2025Article
- Multiomics analysis reveals the involvement of NET1 in tumour immune regulation and malignant progression.Scientific reports · 2025Article
- Recent advances in targeted drug delivery systems for multiple myeloma.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Dendritic Cell-Hitchhiking In Vivo for Vaccine Delivery to Lymph Nodes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy.Biomolecules · 2024Review
- Drug delivery methods for cancer immunotherapy.Drug delivery and translational research · 2024Review
- Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance.Cancers · 2023Review
- Biomedical Approach of Nanotechnology and Biological Risks: A Mini-Review.International journal of molecular sciences · 2023Review
- Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation.Molecular cancer · 2023Review
- Advancement and Applications of Nanotherapy for Cancer Immune Microenvironment.Current medical science · 2023Article
- Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies.Journal of hematology & oncology · 2023Review
- Computational and Experimental Evaluation of the Immune Response of Neoantigens for Personalized Vaccine Design.International journal of molecular sciences · 2023Article
- Insertion of an immunodominant T helper cell epitope within the Group AFrontiers in immunology · 2023Article
- Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment.Biomolecules · 2022Review
- Pathogenesis and treatment of multiple myeloma.MedComm · 2022Review
- The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.International journal of molecular sciences · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
The purpose of these studies was to develop and characterize B-cell maturation antigen (BCMA)-specific peptide-encapsulated nanoparticle formulations to efficiently evoke BCMA-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.